INTRODUCTION
Asthma is a common respiratory syndrome characterized by partially reversible airflow obstruction, airway hyperresponsiveness, and airway inflammation. The syndrome is caused by a complex interaction between genetic and environmental factors that results in a spectrum of biologic and clinical features. Among the spectrum of features is a highly variable response to asthma therapeutics. There are currently three major classes of asthma therapeutics available: (1) beta 2 -agonists (␤-agonist); (2) glucocorticoids (GC); and (3) inhibitors of the cysteinyl-leukotriene pathway (cLI). Asthmatic patients vary greatly in their response to all three classes of drugs and it is estimated that up to 60-80% of this variability may have a pharmacogenetic basis. Over the past 10 years, several polymorphic loci have been discovered in genes that play a role in the action of these drugs. Data suggest that these polymorphisms directly or indirectly alter an asthmatic's response to therapy and can be used to predict the response to certain asthma drugs, thereby maximizing efficacy and avoiding adverse effects. It is likely that many, as yet undiscovered, polymorphisms exist given the large number of gene products involved in the pharmacodynamic and pharmacokinetic pathways of all three classes of asthma drugs. In this review we discuss the established asthma pharmacogenetic loci and describe a candidate gene approach that is being used to uncover additional polymorphisms with pharmacogenetic potential.
ASTHMA AND ITS TREATMENT
Asthma is a clinical syndrome with three defining characteristics: (1) recurrent episodes of airway obstruction that resolve either spontaneously or as a result of therapy; (2) increased airway hyperresponsiveness, which is an increased bronchoconstrictor response to stimuli that would have little or no effect in nonasthmatic subjects; and (3) chronic airway inflammation, often with abundant eosinophils. [1] [2] [3] Asthma severity is usually measured by the presence or absence of symptoms, the frequency of exacerbations, and the degree of airflow resistance as measured by the forced expiratory volume in one second (FEV 1 ). As a clinical problem, asthma is both prevalent and associated with substantial morbidity. There are approximately 17 million asthmatic patients in the United States (6% of the adult population), and asthma is the number one cause of hospitalizations and emergency room visits for children. The health care costs approximate 8 billion dollars per year of which 35-40% are due to medication costs. Moreover, the problem has been getting worse with a worldwide increase in prevalence of 30% over the two past decades. 4 Strategies to more effectively treat this syndrome would be of great benefit. While much is known about the pathobiology of asthma and the inflammatory mediators and effector cells that produce the clinical phenotype, the genetic and environmental causes of the disease have remained obscure (reviewed in Kay, 5 and Holgate 6 ). Although a small percentage of asthma cases may result from a single environmental or genetic cause, most cases result from the interaction of multiple genetic and environmental factors. Each of these factors acting alone would be expected to contribute a small amount to the development of asthma. However, when combined with other factors, the ultimate phenotype or a particular characteristic of an individual's phenotype, such as atopy, severity, or response to a drug is established. Moreover, since asthma is a syndrome reflecting many pathophysiologic pathways, it is likely that different sets of genes and environmental factors lead to asthma or a particular phenotype in different patients or populations. Thus, although several studies based on linkage analysis have defined genomic regions of interest, it should come as no surprise that a single 'asthma gene' has not been identified. 7, 8 Nevertheless, these genome-wide searches for linkage have consistently identified important chromosomal regions that have highlighted known genes as being good 'asthma candidates' with the potential to contribute to the asthma phenotype if a particular allele is present in an individual.
At the cellular level, eosinophils, mast cells, alveolar macrophages, lymphocytes and neutrophils recruited to the airways of asthmatics produce a variety of inflammatory mediators, such as histamine, kinins, neuropeptides, and leukotrienes, which lead to bronchial smooth muscle constriction and obstruction of airflow, and the perpetuation of airway inflammation. 9 , 10 An understanding of the inflammatory processes and the mol-ecular pathways of these mediators has led to the development and widespread use of several pharmacologic agents that mitigate airway inflammation and bronchoconstriction. Three major classes of asthma therapeutics are currently in use: (1) ␤-agonist (eg albuterol, salmeterol, fenoterol); (2) GC (eg, beclomethasone, triamcinolone, prednisone); and (3) cLI (eg, montelukast, zafirlukast, zileuton). In the early 1990s, a classification scheme was developed for defining asthma severity and choosing appropriate regimens from among these classes of drugs.
2 Reliever drugs (inhaled, short acting ␤-agonist) are usually adequate for mild intermittent asthma and provide rapid 'rescue' for acute airway obstruction when it infrequently occurs. In contrast, Controller drugs (inhaled GC, long acting ␤-agonist, and cLI) are necessary for mild, moderate or severe persistent asthma in addition to reliever drugs, because they modify the airway environment, and lessen the frequency of acute airway narrowing in the more symptomatic patients. When asthmatics are treated according to these established guidelines, the vast majority of patients can be effectively managed with minimal morbidity, whether it is directly related to asthma or indirectly caused by drug toxicity. However, there is an important caveat that must be considered with this statementnot all asthmatics are the same and there is tremendous heterogeneity in therapeutic response to each asthma drug. 
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the montelukast group 11 ( Figure 1 ). However, when these same data are viewed from a different perspective, focusing on the number of individuals as a function of percent change in FEV 1 from baseline, it is clear that many patients had little response. In fact, several patients appear to have had an adverse response to treatment with a decline in FEV 1 at 12 weeks compared with baseline ( Figure 2 ). The increase in mean FEV 1 for all patients is eschewed by a dramatic increase in a few individuals. Furthermore, a careful analysis of these studies indicates that individuals responsive to one class of asthma drug may not necessarily be the individuals responsive to a different class of asthma drug. These types of data illustrating variable drug efficacy are not limited to asthma drug trials but can be found for almost all classes of drugs. The degree to which this inter-individual variability is genetic remains uncertain and probably differs with each class of drug. Moreover, inter-individual variability may depend on the particular preparation within a class of asthma drug. Calculations based on the Repeatability (r) of the treatment response for all three classes of asthma drugs, defined as the fraction of the total population variance which results from among individual differences, shows values for r between 60-80% indicating the upper limit of the genetic component and suggests that a substantial fraction of the variance of the treatment response could be genetic in nature. 12 The ultimate goal of asthma pharmacogenetics is to identify this genetic information and use it to tailor an individual's therapeutic regimen in order to maximize efficacy and minimize side effects.
Asthma Pharmacogenetics
Obviously, sequence variants that lead to the identification of novel metabolic pathways or novel mechanisms for inflammation would have great potential for the development of new drugs. However, such fortuitous discoveries are unlikely to occur very often, and will not represent the majority of pharmacogenetic paradigms. There are three general para- digms by which sequence variants may lead to heterogeneity in therapeutic response and impact asthma treatment ( Table 1 ). The most obvious and best-described paradigm in pharmacogenetics is sequence variants that alter the metabolism, distribution or excretion of a drug resulting in enhanced or inhibited drug effects (pharmacokinetic). A second paradigm involves sequence variants that result Table 1 Pharmacogenetic paradigms with implications for asthma treatment (1) Genetic variants associated with altered uptake, distribution, or metabolism of drug (Pharmacokinetic).
(2) Genetic variants resulting in an unintended action of a drug outside of its therapeutic indication (Idiosyncratic).
(3) Genetic variation in the drug target leading to altered drug efficacy (Pharmacodynamic).
www.nature.com/tpj in an unintended consequence of a drug outside of its therapeutic target (idiosyncratic). A third possible paradigm consists of sequence variants in the drug target or the drug target pathway that leads to altered drug efficacy (pharmacodynamic) or a difference in the phenotypic expression of asthma. With regard to asthma pharmacogenetics, only examples of the pharmacodynamic paradigm have been conclusively demonstrated. These examples will be discussed for each category of asthma drug after a brief review of the relevant pharmacodynamic pathway.
PHARMACOGENETICS OF ␤-AGONISTS IN ASTHMA
␤-agonists, such as albuterol, act via binding to ␤ 2 -adrenergic receptors (␤ 2 AR), a cell surface G proteincoupled receptor ( Figure 3 ). ␤ 2 AR primarily couple to the stimulatory guanine nucleotide-binding protein, G s . 13 G s is a heterotrimeric G protein, which upon activation by receptor dissociates into ␣ and ␤␥ subunits. G ␣s stimulates adenylyl cyclase (AC) to catalyze the conversion of ATP to cAMP. The ␤␥ subunits, particularly from Gi, also carry out signal transduction in some cells, including alteration of the activities of AC and phospholipase C (PLC) and activation of the mitogenactivated protein kinase (MAP-kinase). The bronchodilating action of ␤ 2 AR is due primarily to G ␣s activation of adenylyl cyclase in bronchial smooth muscle, with resultant increases in intracellular cAMP.
14 cAMP activates protein kinase A (PKA), which acts to phosphorylate myosin light-chain kinase, cell surface potassium channels, a sodium potassium ATPase, phospholamban, and one or more pumps that lead the sarcoplasmic reticulum to calcium uptake and inhibition of inositol phosphates. The net effect is a decrease in intracellular calcium and phosphorylation of contractile proteins, which leads to smooth muscle relaxation.
15 ␤ 2 AR function is dampened by its phosphorylation by the ␤AR kinase and the binding of ␤arrestin. PKA phosphorylation of ␤ 2 AR also uncouples the receptor and promoters promote coupling to Gi.
␤ 2 AR, as well as other cell surface G protein-coupled receptors, can natively toggle in the absence of agonist between the activated (R A , also called R*) and inactivated (R I , also called R) state. 16 In the absence of agonist, the majority of receptors are in the R I state. In the presence of agonist, R A is stabilized and accumulates such that this state predominates. Inverse agonists stabilize the R I state thereby lowering basal AC activity. Partial agonists stabilize the R A conformation but not as efficiently as full agonists, such that maximal partial agonist-stimulated AC activity is less than that found with full agonists. Neutral antagonists stabilize both R A and R I . Agonist binding also initiates a series of events leading to a loss of ␤ 2 AR function over time. This waning of the response despite continuous stimulation is termed desensitization. 17 ␤ 2 AR and many other G protein-coupled receptors can undergo agonist-specific desensitization (termed homologous) or heterologous desensitization due to actions of ligands at other receptors and their resultant intracellular signaling. Clinically, desensitization is typically termed tachyphylaxis, which refers to a loss of clinical effectiveness of a therapeutic agent upon repetitive administration. In asthma, chronic ␤-agonist administration has been associated with tachyphylaxis in some 18, 19 but clearly not all 20, 21 studies. In addition, excessive ␤-agonist use has been associated with increased asthma mortality 22 and morbidity. 23 These associations with excess ␤-agonist use are not universally found, though, and it is not known whether tachyphylaxis per se is the basis of such observations.
To explain inter-individual differences in response to ␤-agonist and sporadic reports of tachyphylaxis, Liggett and colleagues hypothesized that sequence variants exist in the genes of the ␤-agonist pathway and alter protein function or gene expression. Efforts focused on the ␤ 2 AR gene, an intronless gene localized to chromosome 5q31-32, because of its direct
The Pharmacogenomics Journal interaction with ␤-agonist and its central role in the ␤-agonist pathway; however, sequence variants in many other candidate genes are possible given the large number of interacting proteins comprising the ␤-agonist pathway. Early studies revealed four coding regions and one promoter polymorphism by directly sequencing PCR-derived fragments in cohorts of normal and asthmatic subjects ( Table 2) . At amino acid position 16 Arg or Gly can be present, and at position 27 Gln or Glu can be present. These represent the common coding [24] [25] [26] have been found except for one report in pediatric asthma. 27 It is thus unlikely that any of these polymorphisms or combination of polymorphisms is a major risk factor for asthma.
The effects of these sequence variants on gene expression and receptor function at a molecular level have been the subjects of intense research efforts. For example, direct comparisons of the wild-type and mutant forms of the ␤ 2 AR in vitro indicate that the agonist and antagonist binding affinities and coupling efficiencies to AC of the Gly16 and Glu27 receptors are similar to those of the so-called wild-type receptor; [28] [29] [30] however, there are clear differences in agonist trafficking of these receptors. The Gly16 receptor undergoes enhanced downregulation (loss of receptor number) compared with the wild-type Arg16 receptor. In contrast, the Glu27 receptor undergoes no downregulation compared with the wild-type receptor. Additional studies showed that these alterations in downregulation occur at a step distal to the internalization process, at the point where degradation or recycling to the cell surface occurs. The polymorphism at position Ϫ47, localized within a small open reading frame encoding a peptide that modulates translation of ␤ 2 AR, has been shown to affect ␤ 2 AR expression. 31 These in vitro observations are consistent with many clinical studies examining potential roles of ␤ 2 AR polymorphisms in asthma. Some of these clinical studies have examined potential disease modifying effects, such as severity, 32 phenotype, 33,34 and physiologic parameters. 35 A few studies have examined pharmacogenetic relationships between these polymorphisms and the response to ␤-agonists. For example, Martinez et al 36 examined the bronchodilating response to the administration of a single dose of albuterol in children. The study group consisted of 191 normal children and 78 children with a history of wheezing. Of this latter group 37 had a diagnosis of asthma. In the asthmatic group, 60% of those with homozygous Arg16 had a positive (Ͼ15.3% increase in FEV 1 ) response to albuterol, compared with 13.3% who were homozygous for Gly16. While borderline statistically significant (P = 0.05 for trend), it should be noted that the homozygous Arg16 group consisted of only five patients. Children with a history of wheezing failed to have a statistically significant difference, while normal children again showed a greater percentage of positive responses in the homozygous Arg16 group (P = 0.04). When the groups were analyzed together, the odds ratio for having a positive bronchodilator response to albuterol (adjusted for asthma and wheezing) was 5.3 for homozygous Arg16 children (P = 0.007). This study suggests that the initial response to albuterol in children is affected by ␤ 2 AR genotype at position 16, although the data in asthmatics suffer from a small sample size. The results suggest that the Gly16 receptor is chronically downregulated (presumably by endogenous catecholamines), thereby resulting in a depressed response to the initial dose of albuterol.
Recently, Hancox and colleagues 37 reported the genotypes of a group of 61 asthmatics treated with regular vs as-needed fenoterol. 23 An earlier report showed deterioration in asthma control with regularly scheduled fenoterol treatment compared with as-needed treatment. During treatment with regularly scheduled fenoterol, subjects who were homozygous for Arg16 had an increase in bronchial responsivewww.nature.com/tpj ness to methacholine compared with their responsiveness when they did not receive regular treatment. This finding is consistent with patients who are homozygous for the Arg 16 form of the ␤ 2 AR being predisposed to an adverse reaction to the regularly scheduled use of this ␤-agonist.
An Asthma Clinical Research Network (ACRN) study was performed to assess whether chronic regular-use albuterol was associated with deleterious clinical or physiologic sequella compared with as-needed dosing in mild stable asthmatics. 20 The study was a 16-week, placebo-controlled, double-blind design with 255 asthmatics. For the entire population the results showed that, on average, regularly scheduled (two puffs, four times a day) albuterol had no clinical or physiological deleterious effects compared with an as-needed schedule. Although, tachyphylaxis was not observed in the entire group, some individuals did display tachyphylaxis, particularly in the group allocated to regular albuterol use. Thus we hypo- 
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thesized that tachyphylaxis to albuterol was associated with a ␤ 2 AR genotype. To test this hypothesis, genotyping at the ␤ 2 AR 16 and 27 positions was carried out with genomic DNA obtained from 190 patients. 38 Individuals with the Arg/Arg genotype receiving regularly scheduled albuterol experienced a significant decline in AM peak expiratory flow rate (PEFR) over the course of the study (P = 0.012) (Figure 4 ). This tachyphylaxis was not observed when treatment was given on an as-needed basis to patients with the same genotype. In contrast, those with the Gly/Gly genotype, even when receiving regularly scheduled albuterol, showed no tachyphylaxis. A similar pattern was observed with PM PEFR. The findings were not influenced by the position 27 genotype, race, sex, or initial lung function. We conclude from these data that polymorphisms of the ␤ 2 AR at locus 16 are a significant genetic predictor of tachyphylaxis to the ␤-agonist albuterol. Our results are consistent with the notion that the Gly16 receptor is downregulated maximally by endogenous catecholamines and thus cannot display additional downregulation by albuterol. On the other hand, the Arg16 receptor is less downregulated by endogenous catecholamines, but is downregulated with chronic administration of albuterol. This concept of dynamic regulation 13 is consistent with the results of Martinez et al, 36 which showed a decreased initial response to albuterol in patients homozygous for Gly16. Additional studies are underway to determine if genotypic data can be used prospectively to prevent tachyphylaxis.
We have also recently shown that the 5Ј upstream promoter region of the ␤ 2 AR gene is highly polymorphic. Indeed, there are at least 13 SNPs in the promoter and coding blocks of this gene. Of the 2 13 = 8192 possible combinations of these SNPs, there are only 12 haplotypes that we could identify in an index reporting consisting of four ethnic groups. 39 In a recombinant expression system, certain haplotypes appeared to differentially affect receptor function. For patients bearing the low expression haplotype, the bronchoconstrictor response to albuterol was found to be depressed as compared to those with other haplotypes. These data suggest that in highly polymorphic genes it will be important to consider SNPs within the context. That is, as they appear with other SNPs rather than in isolation.
PHARMACOGENETICS OF GLUCOCORTICOIDS IN ASTHMA
GC exert their biological effects by passively penetrating the plasma membrane of target cells and binding to a specific cytoplasmic glucocorticoid receptor (GR). The GR has three major domains: (a) the hormone-or ligand-binding domain at the COOHterminus; (b) the DNA-binding domain with zinc finger structures that confer high affinity for glucocorticoid response elements (GRE); and (c) an amino-terminal transcription regulatory domain. 40 The unliganded receptor is thought to be a heterohexamer containing the receptor with a single GC-binding and DNA-binding subunit, two molecules of heat shock
The Pharmacogenomics Journal protein (hsp) 90, and one molecule each of hsp 70, hsp 56, hsp 26, and other proteins. 41 The binding of GC to the GR results in dissociation of the hsp subunits and exposure of the DNA binding site on the GR. The activated GR nuclear complex regulates transcription by binding to specific palindromic sequences of DNA, ie, GRE, or by direct interactions with other transcription factors. Usually, two GRE half sites are arranged as inverted palindromes, allowing the GR to bind the DNA as a homodimer. This interaction changes the rate of transcription and results in either induction or repression of gene expression. Administration of GC to asthmatics, either parenterally or directly to the airways by metered dose inhalers, has profound anti-inflammatory effects due to their ability to alter the expression of many pro-inflammatory genes ( Figure 5 ). Sequence variants in the genes encoding for the GR, nuclear proteins that interact with the GR, or There is only one GR gene located on chromosome 5q31. However, cloning of the human GR cDNA and gene has revealed that alternative splicing of the GR pre-mRNA generates two homologous protein isoforms, termed GR␣ and GR␤. 42 These two protein isoforms have the same first 727 NH 2 -terminal amino acids in common and thus both contain the DNA binding domain. GR␣ is the ligand-activated transcription factor which, in the hormone-bound state, modulates the expression of GC-responsive genes. GR␤ differs from GR␣ only in its COOH-terminus, with replacement of the last 50 amino acids of the latter with a unique 15-amino acid sequence. These differences render GR␤ unable to bind GCs and reduce its binding affinity for DNA recognition sites and its ability to transactivate GC-sensitive genes. [43] [44] [45] [46] The importance of the GR in determining clinical responsiveness to GC is supported by the discovery of mutations in the GR, as is best illustrated in primary cortisol resistance. 47 These patients present with elevated total plasma cortisol concentrations, but no Cushingoid features. The molecular basis for GC resistance in the various reported kindreds includes reduced GR numbers, decreased binding affinity for GC, or poor DNA binding of their GR to GRE. 48, 49 Although most asthmatics respond to GC therapy, a subset of asthmatics have poorly controlled asthma even when treated with systemic GC. These patients have been referred to as steroid-resistant or steroid-insensitive asthmatics. In a recent workshop on GC insensitivity in asthma, it was proposed that GC-resistant asthma could be defined by the failure to improve baseline morning prebronchodilator FEV 1 Ͼ15% following at least 7-14 days of 20 mg twice-daily oral prednisone or its equivalent. It should also be pointed out that in most patients, steroid resistance is not an absolute state but a significant shift in the doseresponse curve such that these patients require much higher quantities of GC for optimal response to therapy than patients with steroidsensitive asthma. 50 Studies carried out in our laboratory and others have demonstrated that patients with GCresistant asthma have decreased cellular immune responses to GC. 51, 52 These abnormalities involving their T cells, monocytes, and eosinophils make GC treatment less effective in suppressing the activation of cells from GC-resistant asthmatics than from GC-sensitive asthmatics.
To elucidate the genetic basis of GCresistant asthmatics, screening of many pro-inflammatory genes regulated by GC for sequence variants with pharmacogenetic effects has begun. Much of this effort has focused on the many cytokines regulating T-lymphocytes phenotype, a characteristic central to the development of asthma and other allergic diseases 5 and profoundly altered by GC. These cytokines, which include ILs-3, 4, 5, 9, and 13 and granulocyte-macrophage colony-stimulating factor (GM-CSF), regulate several www.nature.com/tpj processes associated with the atopic state including IgE isotype switching, mast cell proliferation, and eosinophil survival and activation. Several investigative groups studying families with diverse phenotypes, all of which are relevant to asthma (IgE levels, skin-test reactivity, airway responsiveness, or a diagnosis of asthma itself), have identified genetic linkage of the presence of these phenotypes to a region on human chromosome 5q31-33 in which the genes encoding many T cell cytokines, including those encoding for ILs-3, 4, 5, 9, 12␤, and 13 and GM-CSF, are clustered. [53] [54] [55] [56] Although genetic loci directly related to GC-resistant asthma have yet to been determined, sequence variants associated with asthma, asthma severity and atopy have been detected in the IL-4 promoter (Ϫ590, C to T), TNF-␣ promoter (Ϫ308, A to G), and Fc⑀RI␤ (576, Ala to Arg) in some but not all studies.
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PHARMACOGENETICS OF LEUKOTRIENES IN ASTHMA
The leukotrienes are a family of polyunsaturated lipoxygenated eicosatetraenoic acids that are derived from arachidonic acid and exhibit a wide range of pharmacological and physiological actions. 60, 61 In biological systems, their actions are limited by their relative rates of synthesis and degradation. 62, 63 Of the three enzymes exclusively involved in the formation of the leukotrienes, namely ALOX5, LTC 4 synthase, and LTA 4 epoxide hydrolase, ALOX5 is the enzyme required for the production of both the cysteinyl leukotrienes (LTC 4 , LTD 4 , and LTE 4 and LTB 4 ( Figure 6 ). Over the past 10 years, it has been shown that pharmacological inhibition of the action of ALOX5 or antagonism of the action of the cysteinyl leukotrienes at their receptor is associated with an amelioration of asthma. 64 Although a variety of biological actions have been ascribed to LTB 4 , it is predominantly a chemotactic moiety for eosinophils and neutrophils; 65, 66 these actions occur via signal transduction at the LTB 4 receptors. 67 The cysteinyl leukotrienes were identified as a result of the search for the chemical structure of the materials that constituted the contractile activity known as slow-reacting sub-stance of anaphylaxis (SRS-A) 60, 61 and are among the most potent bronchoconstrictor substances ever identified; 68, 69 their actions result from signal transduction at the CysLT 1 receptor. In addition, a myriad of other, mostly proinflammatory biological activities have been attributed to the cysteinyl leukotrienes, from mitogenic effects to the modification of vascular integrity (see reviews by Badr, 70 Bend & Karmazyn, 71 and Denzlinger 72 ). Among the human disease conditions thought to result from excess availability of the cysteinyl leukotrienes is asthma. 64, 73 Inhibition of ALOX5 activity or blockade of the CysLT 1 receptor by cLI is associated with clinically significant improvements in asthma outcome. 74 The regulation of ALOX5 is multifaceted; known mechanisms include regulation of action of the mature protein and regulation of ALOX5 gene transcription and translation. The ALOX5 gene promoter contains numerous consensus binding sites for many known transcription factors, including Sp1, Sp3, Egr-1, Egr-2, NFkB, GATA, Myb, and AP family members.
Of particular importance, Hoshiko et al 75 have identified a GϩC-rich sequence, between Ϫ212 and Ϫ88 bp relative to the translational start site, as being necessary for promoter-reporter construct activity in HeLa and HL-60 cells; these observations, which we have confirmed, led us to examine this region of the ALOX5 promoter for mutations that might alter gene transcription. We identified a family of naturally occurring mutations that alter Sp1 and Egr-1 consensus binding sites by the addition of one or the deletion of one or two -GGGCGGsequences ( Figure 7) . 76 Sp1 and Egr-1 were capable of binding this region of the promoter, and the mutations altered the pattern of binding as detected by electrophoretic mobility shift assays (EMSAs) with nuclear extracts and recombinant protein. Moreover, these mutations had significant functional consequences when studied in the context of CAT reporter constructs. 77 These data indicated that the various polymorphisms we identified were
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more than a simple tandem nucleotide repeat; rather, they were positioned so as to modify gene transcription and therefore to potentially modify ALOX5 product formation.
The significance of these promoter polymorphisms has been examined from a pharmacogenetic perspective as part of a clinical drug trial examining the effects of ABT-761, a ALOX5 inhibitor similar to zileuton, in patients with asthma. 78 As expected, ABT-761 resulted in a significant improvement in asthma as measured by FEV 1 compared with placebo control. When the 221 individuals who received either high-dose ABT-761 (n = 114) or placebo (n = 107) treatment for 84 days were stratified by genotype at the ALOX5 core promoter locus, dramatic differences in response were detected (Figure 8) . Patients with the wild-type allele had an approximate 19% improvement in FEV 1 , com-pared with Ϫ1% in FEV1 among individuals with mutant alleles (P = 2.5 ϫ 10
Ϫ5
). These data are consistent with the idea that individuals harboring any of the mutant forms of the ALOX5 core promoter have decreased ALOX5 gene transcription and thus downregulated ALOX5 expression. If ALOX5 products were among the several mediators contributing to the airway obstruction in asthma, and if patients harboring the mutant genotypes were equivalent to patients who were receiving ABT-761 treatment that inhibited ALOX5, then the former patients would have airway obstruction mediated by mechanisms other than the leukotrienes. As a consequence of this natural inhibition, patients harboring the mutant genotypes have a diminished response to exogenous ALOX5 inhibition. It may be possible to genotype asthmatics at the ALOX-5 locus and predict which patients will improve with leukotriene inhibitors; asthmatics with mutant alleles at the ALOX-5 should probably avoid cLI because they are unlikely to derive clinical benefit.
CONCLUSION
The pharmacogenetic associations discussed for each therapeutic pathway represent only a small fraction of the genetic variability responsible for differences in drug response. Only the central components have been considered and it should be emphasized that each pathway is extraordinarily complex and modulated by numerous interacting cytokines, chemokines, growth factors, and cofactors. All of the receptors, signal transduction components and transcriptional factors for effector genes must also be considered pharmacogenetic candidates. Pharmacokinetic and idiosyncratic paradigms have not yet been examined in asthma but are likely to be important as well. Many enzymes and transporters are involved in the distribution, metabolism and excretion of asthma drugs, and the genes coding for these proteins may contain significant genetic variability. Moreover, it is becoming clear that each sequence variant cannot be studied in isolation but must be considered www.nature.com/tpj in the context of other sequence variants in the same gene and sequence variants in other genes involved in the pharmacologic pathway. 39 Despite these challenges, significant progress has been made and it is now possible to genotype asthmatics at a few loci and use this information to make therapeutic decisions that improve drug efficacy and mitigate complications. With completion of the human genome sequence, and the availability of high-density single nucleotide polymorphism maps and high-throughput genotyping technology, the pace of newly discovered loci with pharmacogenetic relevance to asthma is likely to increase exponentially over the next few years.
